SNHG17 has subsequently also been found to be overexpressed in lung cancer [14], GC [15], hepatocellular carcinoma [16], osteosarcoma [17, 18] and other tumors, and its expression levels have been reported to be associated with a poor prognosis. This evidence concerns the gene SNHG17 and hepatocellular carcinoma.